|Articles|November 8, 2022
- Pharmaceutical Executive-11-01-2022
- Volume 42
- Issue 11
Pharmaceutical Executive, November 2022 Issue (PDF)
Click the title above for a link to open the Pharmaceutical Executive November 2022 issue in an interactive PDF format.
Advertisement
Articles in this issue
over 3 years ago
A Culture of Quality: The Catalyst to Accelerate Innovationover 3 years ago
A Mission of the Heartover 3 years ago
The New Reality for Industry Dealmaking May be Setting Inover 3 years ago
Is ESG a ‘Protection Racket’ or Long-Term Value Contributor?over 3 years ago
Digital Biomarkers Could Reshape CNS Diagnosis, Treatmentover 3 years ago
Long-Sought Reforms To EU Drug Rules Hit A Snag—What Now?over 3 years ago
Recaps, Live & In Personover 3 years ago
FDA Keeps Its User Fees, but Fails to Gain Important ReformsNewsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
The Influence of Trump Rx in Pharmacy Benefit Managers, Retail Pharmacies, and Digital Health Platforms
2
Leading in the Psychedelic Space: Q&A with Tarek Rabah
3
Boehringer Ingelheim Acquires Exclusive License from Sitryx Therapeutics for Preclinical Small Molecule Program
4
Pharma Leadership Roundup: Sarepta Therapeutics CEO Announces Retirement, Rivus Pharmaceuticals Appoints New CEO
5

